FAQ on Fifty 1 Labs, Inc. and UAV Corp's New CEO Appointment and BioSentry Division Launch

Who has been appointed as the new CEO and Chairman of Fifty 1 Labs, Inc.?

Michael Lawson has been appointed as the new CEO and Chairman of Fifty 1 Labs, Inc.

What is the focus of the newly launched BioSentry Division?

The BioSentry Division focuses on developing real-time sensor systems using PCR, spectrometry, and AI-driven analytics to detect biological, chemical, and environmental threats.

What strategic partnership has Fifty 1 Labs, Inc. announced?

Fifty 1 Labs, Inc. has announced a strategic partnership with UAV Corp (OTC: UMAV) to integrate the BioSentry sensors with UAVs and plans to issue a UMAV share dividend to FITY shareholders.

Will Fifty 1 Labs, Inc. proceed with the Genetic Networks acquisition?

No, Fifty 1 Labs, Inc. has opted not to proceed with the Genetic Networks acquisition and remains focused on securing Department of Defense contracts.

What are the applications of the BioSentry Division’s technologies?

The technologies developed by the BioSentry Division have applications spanning defense, public health, and industrial safety.

Who will continue in key leadership roles at Fifty 1 Labs, Inc.?

Brandon Spikes and Robert Clark will continue in key leadership roles as the company advances its focus on safety and wellness technologies.

Where is Fifty 1 Labs, Inc. based?

Fifty 1 Labs, Inc. is a Nevada corporation based at 751 North Drive, Melbourne, FL 32934.

What is the GeneScape platform?

The GeneScape platform is a yeast-based, whole-genome analysis tool developed by Genetic Networks LLC, a subsidiary of Fifty 1 Labs, Inc., that accelerates drug discovery for personalized medicine, biodefense, and wellness applications.

Where can I find more information about Fifty 1 Labs, Inc.?

For more information, visit the company’s website at https://fifty1labs.com/

Where can I view the full press release?

To view the full press release, visit https://ibn.fm/EMAyM